Literature DB >> 30261276

The role of cancer stem cells in the modulation of anti-tumor immune responses.

Cristina Maccalli1, Kakil Ibrahim Rasul2, Mamoun Elawad3, Soldano Ferrone4.   

Abstract

Tumor lesions comprise multiple subpopulations of cells including those endowed with "stemness" properties. The latter cells are responsible of tumor initiation, metastasis formation, resistance to conventional therapies and disease recurrence. These relatively rare cells denominated cancer stem cells (CSCs) or cancer initiating cells (CICs) are defined based on self-renewing, multipotency and tumorigenicity. These cells through their immunomodulating features can evade from immunesurveillance, persisting in the form of quiescence and dormancy. They can drive the neoplastic growth and recurrence, even after long latency. Moreover, CSCs/CICs due to their ability to modulate and shape immune responses can represent the component of a tumor causing immunotherapy resistance in cancer patients. In this review a general overview of immunological properties of CSCs/CICs is provided, with a special focus on the mechanisms of modulation of T cell mediated responses. The need to further dissect the mechanisms regulating the immunological profile of CSCs/CICs and their interactions with immune cells and tumor microenvironment is discussed. An improved characterization of the immunological properties of CSCs/CICs will contribute to the rationale design of immunotherapeutic interventions which target these cells and may lead to the eradication of malignant diseases.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Immune escape mechanisms; Immune-based interventions; Immunological profiling; Tumor dormancy

Mesh:

Substances:

Year:  2018        PMID: 30261276      PMCID: PMC8668198          DOI: 10.1016/j.semcancer.2018.09.006

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  219 in total

1.  Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.

Authors:  Christine E Brown; Renate Starr; Brenda Aguilar; Andrew F Shami; Catalina Martinez; Massimo D'Apuzzo; Michael E Barish; Stephen J Forman; Michael C Jensen
Journal:  Clin Cancer Res       Date:  2012-03-08       Impact factor: 12.531

Review 2.  Immune checkpoint blockade.

Authors:  Jarushka Naidoo; David B Page; Jedd D Wolchok
Journal:  Hematol Oncol Clin North Am       Date:  2014-06       Impact factor: 3.722

3.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

4.  Cancer stem cells and chemosensitivity.

Authors:  Marcello Maugeri-Saccà; Paolo Vigneri; Ruggero De Maria
Journal:  Clin Cancer Res       Date:  2011-05-27       Impact factor: 12.531

5.  B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells.

Authors:  Yu Yao; Xiaomei Wang; Kunlin Jin; Jianhong Zhu; Yin Wang; Sidong Xiong; Ying Mao; Liangfu Zhou
Journal:  J Neurooncol       Date:  2008-05-14       Impact factor: 4.130

6.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

7.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

8.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.

Authors:  M C Mihm; C G Clemente; N Cascinelli
Journal:  Lab Invest       Date:  1996-01       Impact factor: 5.662

9.  Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.

Authors:  Rena Morita; Satoshi Nishizawa; Toshihiko Torigoe; Akari Takahashi; Yasuaki Tamura; Tomohide Tsukahara; Takayuki Kanaseki; Alice Sokolovskaya; Vitaly Kochin; Toru Kondo; Satoshi Hashino; Masahiro Asaka; Isao Hara; Yoshihiko Hirohashi; Noriyuki Sato
Journal:  Cancer Sci       Date:  2014-02-24       Impact factor: 6.716

10.  Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.

Authors:  Rachel E Beard; Zhili Zheng; Kiran H Lagisetty; William R Burns; Eric Tran; Stephen M Hewitt; Daniel Abate-Daga; Shannon F Rosati; Howard A Fine; Soldano Ferrone; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunother Cancer       Date:  2014-08-19       Impact factor: 13.751

View more
  26 in total

Review 1.  Hypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity.

Authors:  Jin Qian; Erinn B Rankin
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 2.  Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells.

Authors:  Shannon M Clayton; Joehleen A Archard; Joseph Wagner; D Gregory Farwell; Arnaud F Bewley; Angela Beliveau; Andrew Birkeland; Shyam Rao; Marianne Abouyared; Peter C Belafsky; Johnathon D Anderson
Journal:  Stem Cells Dev       Date:  2020-01-30       Impact factor: 3.272

Review 3.  Immunotherapeutics for head and neck squamous cell carcinoma stem cells.

Authors:  X Qian; F Leonard; Y Wenhao; H Sudhoff; T K Hoffmann; S Ferrone; A M Kaufmann; A E Albers
Journal:  HNO       Date:  2020-02       Impact factor: 1.330

Review 4.  The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review.

Authors:  Jin Zhou; Qian Yi; Liling Tang
Journal:  J Exp Clin Cancer Res       Date:  2019-06-11

5.  BMX-ARHGAP fusion protein maintains the tumorigenicity of gastric cancer stem cells by activating the JAK/STAT3 signaling pathway.

Authors:  Xiao-Feng Xu; Feng Gao; Jian-Jiang Wang; Cong Long; Xing Chen; Lan Tao; Liu Yang; Li Ding; Yong Ji
Journal:  Cancer Cell Int       Date:  2019-05-17       Impact factor: 5.722

Review 6.  Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure.

Authors:  Lorenzo Castagnoli; Francesca De Santis; Tatiana Volpari; Claudio Vernieri; Elda Tagliabue; Massimo Di Nicola; Serenella M Pupa
Journal:  Cells       Date:  2020-02-27       Impact factor: 6.600

Review 7.  Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion.

Authors:  Nicholas C DeVito; Michael P Plebanek; Bala Theivanthiran; Brent A Hanks
Journal:  Front Immunol       Date:  2019-12-10       Impact factor: 7.561

Review 8.  Exosomes and Cancer Stem Cells in Cancer Immunity: Current Reports and Future Directions.

Authors:  Na-Kyeong Lee; Vinoth Kumar Kothandan; Sangeetha Kothandan; Youngro Byun; Seung-Rim Hwang
Journal:  Vaccines (Basel)       Date:  2021-05-01

Review 9.  Influence of Innate Immunity on Cancer Cell Stemness.

Authors:  Anna Pastò; Francesca Maria Consonni; Antonio Sica
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

10.  The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy.

Authors:  Shilpa Ravindran; Saad Rasool; Cristina Maccalli
Journal:  Cancer Microenviron       Date:  2019-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.